KB-0118
KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.
For research use only. We do not sell to patients.
- CAS No.: 2648377-08-4
- Formula: C17H11NO5
- Molecular Weight:309.27
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
BRD2 BD1 36.7 μM (Kd) |
BRD2 BD2 74.3 μM (Kd) |
BRD4 BD1 47.4 μM (Kd) |
BRD4 BD2 41.7 μM (Kd) |
STAT3 |
IL-1β |
IL-23a |
In Vitro
KB-0118 (1-10 μM, 12 h) downregulates pro-inflammatory cytokines (eg: TNF, MIF, and CSF2) in PMA (HY-18739)/Lonomycin (HY-122466) treated Jurkat cells[1].
KB-0118 (1-10 μM, 12 h) downregulates pro-inflammatory cytokines (eg: IL-1β, IL-6, IL-23a, and Cxcl11) in LPS (HY-D1056) treated RAW 264.7 cells[1].
KB-0118 (5 μM, 5 days) inhibits anti-CD3 and anti-CD28 activated mouse CD4+ T cells proliferation, as evidenced by decreased division, proliferation, expansion, and replication indices[1].
KB-0118 (5 μM, 5 days) reduces the proportion of Th17 cells (RORγt+ IL-17A+), indicating inhibition of Th17 differentiation[1].
KB-0118 (5 μM, 5 days) increases the proportion of Th2 cells (GATA-3+ IL-4+), suggesting it promotes Th2 polarization[1].
KB-0118 (0.01-1 μM, 24 h) increases cell viability in DSS (5 %, 48 h)-treated Caco-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Jurkat cells
-
Concentration:1 μM, 5 μM, 10 μM
-
Incubation Time:Pretreated for 6 h and then co-incubated with PMA/Lonomycin for 6 h
-
Result:Downregulated pro-inflammatory cytokines, particularly TNF, MIF, and CSF2, TGFB1, and these reductions were statistically significant at 5 μM and 10 μM.
Upregulated IL-3, IL-4, and IL-26.
In Vivo
KB-0118 (50 mg/kg, p.o., daily for 6 weeks) alleviates T cell-mediated colitis by reducing IL-17a-driven inflammation in a chronic T cell-mediated mice colitis model[1].
KB-0118 (50-250 mg/kg, p.o., for 14 days) shows tolerability in male and female C57BL/6 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DSS (HY-116282C) (3 % in drinking water)-induced colitis model in male C57BL/6 mice[1].
-
Dosage:200 mg/kg
-
Administration:In drinking water, for 7days
-
Result:Had a significant protective effect on colon length, preserving colon integrity and reducing inflammation compared to the DSS-only group.
Reduced epithelial damage and immune cell infiltration compared to DSS-only mice.
Provided a slight, non-significant reduction in weight loss and the Disease Activity Index (DAI) compared to DSS-only mice.
-
Animal Model:A chronic colitis model induced by adoptive transfer of CD45RBhigh T cells into RAG1 KO mice[1].
-
Dosage:50 mg/kg
-
Administration:Oral gavage (p.o.), daily for 6 weeks
-
Result:Attenuated weight loss and increased colon length compared to vehicle-treated controls.
Reduced epithelial damage and immune cell infiltration in the colon, showing greater efficacy than MS402 (HY-120000).
Reduced IL-17a levels in the DSS-treated colons.
Down-regulated critical genes for T cell activation and cytotoxicity, such as Cd3e, Lck, and Stat4, as well as integrin genes like Itgam and Itgal (bulk RNA sequencing).
Reduced expression of genes regulated by immune-related TFs, such as IRF8, FOXO1, and RUNX1 (bulk RNA sequencing).
Chemical Information
-
CAS No. 2648377-08-4
-
Molecular Weight 309.27
-
Formula C17H11NO5
-
SMILES
O=C1C(O)=C(C2=CC3=C(C=CN3)C=C2)OC4=C1C(O)=CC(O)=C4
-
Synonyms
BBC0115
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
iPSC cell differentiation
Induced pluripotent stem cells (iPSCs) are a type of cell that has similar properties to embryonic stem cells through somatic cell reprogramming.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)